{"id":"W3037060742","doi":"10.1111/bjd.19341","title":"Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–assessor‐blinded clinical trial*","year":2020,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":206,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université Laval; Centre de Recherche Dermatologique du Québec Métropolitain","funders":"AbbVie","keywords":"Secukinumab; Medicine; Psoriasis Area and Severity Index; Psoriasis; Interleukin 17; Internal medicine; Randomized controlled trial; Clinical endpoint; Confidence interval; Clinical trial; Dermatology; Psoriatic arthritis; Cytokine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high","status":"direct model label, unvalidated"}],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008677997,0.0003964822,0.003399917,0.0002164193,0.0001652141,0.00007043414,0.0006657612,0.0006242921,0.0001405289],"category_scores_gemma":[0.001817433,0.0003576156,0.0002386726,0.0003565947,0.0003516316,0.0002959541,0.0002456053,0.0007537473,0.00001772581],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004382219,"about_ca_system_score_gemma":0.000383516,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002670957,"about_ca_topic_score_gemma":0.0001342383,"domain_scores_codex":[0.9928045,0.002487223,0.00343283,0.0006381455,0.0001536678,0.00048365],"domain_scores_gemma":[0.9947666,0.002622748,0.001800728,0.0002892957,0.0003191877,0.0002014629],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9387372,0.004378005,0.001401783,0.00001333269,0.001980118,0.0006785578,0.0009092697,0.00002240984,0.00007364639,0.00002115146,0.00282358,0.04896095],"study_design_scores_gemma":[0.9838293,0.003200175,0.007947286,0.0003662394,0.0007602341,0.001038974,0.0001070096,0.00001839082,0.00116796,0.00004313163,0.001153676,0.0003676119],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.992528,0.002124223,0.0002346451,0.001375365,0.0008090804,0.002135809,0.000671209,0.00001844376,0.0001032272],"genre_scores_gemma":[0.9970642,0.001158142,0.0008642508,0.0003670645,0.00009351207,0.00003149029,0.0003645289,0.00003838315,0.00001842146],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04859334,"threshold_uncertainty_score":0.9998876,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04242110571347812,"score_gpt":0.3147352210618506,"score_spread":0.2723141153483725,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}